Addex TherapeuticsADXN
13F holders, Q2 2024 (June 30)2holders +1
1new positions
0sold out
$8.22avg. 13F price*
At the end of Q2 2024, 2 institutions reported holding Addex Therapeutics Ltd. (ADXN) in their 13F filings, up 1 from Q1 2024. 1 opened new positions and 0 sold out. The largest holders were Morgan Stanley ($12K) and ADAR1 Capital Management, LLC ($7K).
- Company
- Addex Therapeutics Ltd.
- CUSIP
- 00654J206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $12K |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 2,010 shares bought, net +2,010 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Morgan Stanley | 0.00% | New | 1,500 | $12K |
| ADAR1 Capital Management, LLC | 0.00% | Add +130.8% | 900 | $7K |
"% of holder's portfolio" is ADXN's weight in each manager's 13F, not the share of Addex Therapeutics Ltd. the manager owns.